Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KI YOUNG CHUNG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1336110113
CMS profile
15168
Location
SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$11,246.64

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KI YOUNG CHUNG

NPI 1336110113 · CMS profile ID 15168

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336110113?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336110113?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336110113?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KI YOUNG CHUNG, NPI 1336110113, CMS profile ID 15168, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1336110113?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $11,246.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $18.1105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104786788 CMS
Exelixis Inc. $15.8005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138560680 CMS
Ipsen Biopharmaceuticals, Inc $22.2305/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091964157 CMS
PFIZER INC. $19.4205/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131547752 CMS
JAZZ PHARMACEUTICALS INC. $21.0505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150210187 CMS
E.R. Squibb & Sons, L.L.C. $15.2605/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101324192 CMS
Incyte Corporation $124.5605/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141270810 CMS
PFIZER INC. $18.0905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131305716 CMS
Novartis Pharmaceuticals Corporation $30.5405/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086718185 CMS
Astellas Pharma US Inc $24.8105/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139353485 CMS
Daiichi Sankyo Inc. $21.4905/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089409416 CMS
AstraZeneca Pharmaceuticals LP $13.6605/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105510979 CMS
SpringWorks Therapeutics, Inc. $18.4905/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085803598 CMS
SOBI, INC $16.4204/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141420054 CMS
Lilly USA, LLC $16.4604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135078823 CMS
E.R. Squibb & Sons, L.L.C. $11.4204/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101324178 CMS
PFIZER INC. $23.5004/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131301643 CMS
PFIZER INC. $15.8704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131406877 CMS
Alnylam Pharmaceuticals Inc. $20.6204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125855151 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.5404/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117967281 CMS
Incyte Corporation $28.6104/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141299871 CMS
Daiichi Sankyo Inc. $23.7804/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089409418 CMS
Gilead Sciences, Inc. $31.5004/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133796037 CMS
PFIZER INC. $15.0004/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131321803 CMS
Merck Sharp & Dohme LLC $19.5704/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141828914 CMS
Rigel Pharmaceuticals, Inc. $115.9804/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145197961 CMS
PFIZER INC. $19.3003/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131295624 CMS
Eisai Inc. $1.2703/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110758834 CMS
Eisai Inc. $20.8103/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110758838 CMS
Amgen Inc. $14.9603/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111550502 CMS
Celgene Corporation $21.2503/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101109346 CMS
Novartis Pharmaceuticals Corporation $10.3303/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086718181 CMS
Janssen Biotech, Inc. $17.8103/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078642151 CMS
ABBVIE INC. $20.2203/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103472969 CMS
Novartis Pharmaceuticals Corporation $27.7303/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086718175 CMS
GENZYME CORPORATION $200.0003/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139982792 CMS
Novartis Pharmaceuticals Corporation $21.6603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086718171 CMS
AstraZeneca Pharmaceuticals LP $16.5503/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105510977 CMS
E.R. Squibb & Sons, L.L.C. $17.7303/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101324176 CMS
Novartis Pharmaceuticals Corporation $19.9903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086718173 CMS
SpringWorks Therapeutics, Inc. $121.8003/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085803596 CMS
Regeneron Healthcare Solutions, Inc. $26.3703/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114026086 CMS
Celgene Corporation $18.2502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101109344 CMS
AstraZeneca Pharmaceuticals LP $17.7502/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104786782 CMS
Eisai Inc. $21.5502/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110758830 CMS
Merck Sharp & Dohme LLC $33.4002/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141576875 CMS
BeiGene USA, Inc. $16.0602/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120868330 CMS
Exelixis Inc. $18.1702/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138560678 CMS
AstraZeneca Pharmaceuticals LP $22.0802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104786784 CMS
ABBVIE INC. $10.6302/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103472967 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,662.86 22
PY2020 $2,456.45 9
PY2021 $2,379.01 10
PY2022 $3,311.65 41
PY2023 $11,861.68 146
PY2024 $11,246.64 172
PY2025 $10,646.94 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $627,547.51 52
PY2024 Principal investigator $1,192,196.50 37
PY2023 Principal investigator $730,279.90 32
PY2022 Principal investigator $1,530,194.34 54
PY2021 Principal investigator $106,782.01 27
PY2020 Principal investigator $142,607.48 58
PY2019 Recipient $44.41 1
PY2019 Principal investigator $342,856.70 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Coherus Oncology, Inc. $7,308.00 12/23/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
CHS11402 No dispute reported 06/30/2026 1235252521
Principal investigator 1 PFIZER INC. $60,090.00 12/05/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228738646
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,850.00 10/29/2025 Covered Recipient Teaching Hospital
Ph Patewood Hospital
A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care gemcitabine, cisplatin, and durvalumab for first line locally advanced or metastatic HER2-expressing Biliary Tract Cancer No dispute reported 06/30/2026 1185539417
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,109.85 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995014
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $29.30 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995016
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2.20 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995018
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $373.12 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995020
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $79.92 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995022
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $584.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995024
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $916.05 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995026
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $72.32 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995028
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,448.55 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995030
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995032
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $25.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995034
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.80 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995036
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.00 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995038
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $56.40 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995040
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $52.50 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995042
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $61.50 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995044
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $11.50 10/27/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220995046
Principal investigator 1 Boehringer Ingelheim International GmbH $325.57 10/01/2025 Non-covered Recipient Entity
Institute For Translational Oncology Research
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220643194
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $3,404.00 09/12/2025 Covered Recipient Teaching Hospital
Oconee Memorial Hospital
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation No dispute reported 06/30/2026 1184285761
Principal investigator 1 BioNTech SE $270.00 09/10/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018400
Principal investigator 1 BioNTech SE $90.00 09/10/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018402
Principal investigator 1 BioNTech SE $1,500.00 09/10/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018404
Principal investigator 1 BioNTech SE $1,994.00 07/14/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018406
Principal investigator 1 BioNTech SE $250.00 07/14/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
BNT321-02 No dispute reported 06/30/2026 1249018408
Principal investigator 1 Coherus Oncology, Inc. $20,200.00 06/26/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
CHS38802 No dispute reported 06/30/2026 1235252559
Principal investigator 1 PFIZER INC. $21,880.00 05/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755061
Principal investigator 1 PFIZER INC. $43,996.68 05/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755812
Principal investigator 1 PFIZER INC. $21,880.00 05/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228756704
Principal investigator 1 PFIZER INC. $43,996.68 05/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228757865
Principal investigator 1 Coherus Oncology, Inc. $21,700.00 05/13/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
CHS11402 No dispute reported 06/30/2026 1235252517
Principal investigator 1 Ipsen Bioscience Inc. $1,282.00 04/04/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas No dispute reported 06/30/2026 1176544941
Principal investigator 1 PFIZER INC. $21,998.34 03/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755000
Principal investigator 1 PFIZER INC. $12,467.36 03/20/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755901
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $9,651.33 03/19/2025 Covered Recipient Teaching Hospital
Oconee Memorial Hospital
A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation No dispute reported 06/30/2026 1184285759
Principal investigator 1 PFIZER INC. $12,467.36 03/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228757203
Principal investigator 1 PFIZER INC. $21,998.34 03/19/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758217
Principal investigator 1 Astellas Pharma Global Development $1,246.00 03/07/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma No dispute reported 06/30/2026 1234179998
Principal investigator 1 PFIZER INC. $6,233.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228755394
Principal investigator 1 PFIZER INC. $43,996.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758013
Principal investigator 1 PFIZER INC. $43,996.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758017
Principal investigator 1 PFIZER INC. $6,233.68 02/25/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758191
Principal investigator 1 PFIZER INC. $6,233.68 02/24/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228720041
Principal investigator 1 PFIZER INC. $43,996.68 02/24/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228756707
Principal investigator 1 PFIZER INC. $43,996.68 02/20/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228743565
Principal investigator 1 PFIZER INC. $6,233.68 02/20/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228754983
Principal investigator 1 PFIZER INC. $12,467.36 01/14/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228758834
Principal investigator 1 PFIZER INC. $21,998.34 01/14/2025 Non-covered Recipient Entity
Prisma Health Cancer Institute
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228759165
Principal investigator 1 PFIZER INC. $21,998.34 01/13/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228754553
Principal investigator 1 PFIZER INC. $12,467.36 01/13/2025 Covered Recipient Teaching Hospital
Ghs Greenville Memorial Hospital
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228754598